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Abstract 
Background: Autologous blood transfusion is a common technique in cardiac surgery to directly re‑infuse residual 
blood from the cardiopulmonary bypass (CPB) circuit to the patient. The objective of this study was to evaluate the 
effects of reinfusion of unprocessed residual pump blood on the coagulation system after separation from the CPB 
circuit and reversal of systemic heparin with protamine.
Measurements and main results: After ethics approval, 40 participants undergoing cardiac surgery were recruited 
in a prospective single center cohort study. Changes in coagulation were assessed with standard plasma based 
laboratory assays and thromboelastography. After the reinfusion of unprocessed residual pump blood there were 
decreases in the mean aPTT (effect size 6 s; SD: 6.05; p < 0.0001) and thrombin time (effect size 4.08 s; SD: 9.7; 
p = 0.01). There were no significant changes in PT, INR and D‑dimer. Post reinfusion there were increases in fibrino‑
gen, hemoglobin and platelet counts. There were improvements in the R‑time (effect size 9.1 s; SD: 16.9; p = 0.0023), 
K‑time (effect size 1.5 s; SD: 3.6 s; p = 0.0017), alpha angle (6.9°; SD: 15.8; p = 0.012), and maximum amplitude 
(3.0 mm; SD: 5.6, p = 0.002) on thromboelastography.
Conclusion: The reinfusion of unprocessed residual CPB blood resulted in no deleterious effects on the coagu‑
lation system measured by both the common laboratory plasma based measurements of coagulation and 
thromboelastography.
Keywords: Blood salvage, Autologous blood transfusion, Cardiopulmonary bypass residual blood, 
Thromboelastography
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Background
In cardiac surgery, the transfusion of red blood cells is 
considered beneficial in  situations in which a critically 
low hematocrit may contribute to inadequate tissue oxy-
gen delivery. Risks associated with transfusion of allo-
geneic blood include bacterial and viral contamination, 
transfusion-associated lung injury, and transfusion-asso-
ciated immunological risks including incompatibility of a 
transfusion with donor ABO group antigens, allo-immu-
nization; immunization with the HLA group antigens and 
transfusion-mediated immunomodulation [1]. In cardiac 
surgery, autologous transfusion (collection and reinfusion 
of the patient’s own blood) is therefore a common tech-
nique. This may involve reinfusion of washed red blood 
cells after collection using a cell salvage device. However, 
a more widely used technique is the direct reinfusion of 
unprocessed (unwashed) residual blood from the cardio-
pulmonary bypass (CBP) circuit after separation from 
CPB and reversal of systemic heparin with protamine. 
The advantages of this include increased hematocrit and 
hemoglobin values [2], greater thrombin generation, 
fibrinolysis activation and lower fibrinolysis inhibition 
[3]. However, as the unprocessed residual blood from the 
CPB is heparinised, it is a common assumption that a “re-
heparin” effect frequently develops with adverse effects 
on the coagulation system. Therefore we hypothesised 
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that the reinfusion of heparinised autologous blood 
administered after separation from the CPB circuit and 
complete reversal of systemic heparin with protamine, 
leads to prolongation of the common laboratory plasma 
based measurement of coagulation and derangements 




The Austin Health Research and Ethics Committee 
approved this study (number: LNR/13/Austin/291/2013) 
and all participants gave written informed consent. 
Between January 2013 and June 2013 participants were 
recruited from perioperative anesthesia and cardiac clin-
ics at the Austin Hospital, a large University-affiliated, 
metropolitan hospital in Melbourne, Australia. Inclusion 
criteria included adult patients (>18  years) undergoing 
either primary coronary artery bypass graft or valve sur-
gery requiring CPB. Exclusion criteria included a history 
of bleeding disorders, any preoperative abnormality in 
the common laboratory plasma based measurement of 
coagulation, thrombocytopenia, abnormal liver function 
tests, redo surgery, history of endocarditis, and preop-
erative use within a 10-day period of any of the following 
medications; warfarin, heparin (high or low molecular 
weight), adenosine diphosphate receptor inhibitors, gly-
coprotein IIB/IIIA inhibitors, adenosine re-uptake inhib-
itors or thromboxane inhibitors.
Primary outcomes
The primary aim was to evaluate changes in coagulation 
after the reinfusion of the unprocessed residual hep-
arinised blood from the CPB circuit administered after 
separation from the CPB circuit and complete reversal 
of systemic heparin with protamine. Standard plasma 
based laboratory assays of coagulation were used to 
measure aPTT, prothrombin time (PT), thrombin time 
(TT), D-dimer, and fibrinogen. As these standard labora-
tory assays are often considered to be poor predictors of 
bleeding and thrombosis, thromboelastography was used 
to measure the viscoelastic properties of whole blood 
clot formation. Hemoglobin (by absorption spectropho-
tometry) and platelet count (using impedance method-
ology with hydrodynamic focusing) were also measured 
using a Sysmex XE5000 analyser (Sysmex corporation, 
Japan). Laboratory coagulation tests were performed 
using an ACL TOP 500 analyser (Instrumentation Lab-
oratory, USA). The PT was measured using a clot based 
assay using recombinant tissue factor relipidated in a 
synthetic phospholipid blend combined with calcium 
chloride (PT-Recombiplastin reagent, Instrumenta-
tion Laboratory, USA). Fibrinogen was derived from 
absorbance during the PT clot based assay relative to a 
calibrator (PT-Recombiplastin reagent, Instrumentation 
Laboratory, USA). The TT used a clot based assay using 
purified bovine thrombin to convert fibrinogen to fibrin 
(Thrombin Time reagent, Instrumentation Laboratory, 
USA). D-Dimer was measured using a latex enhanced 
immunoassay (D-Dimer HS reagent, Instrumentation 
Laboratory, USA). The aPTT was measured using clot 
based assay using purified phospholipid and micronized 
silica activator (Triniclot HS reagent, TCOAG, Ireland). 
The viscoelastic properties of whole blood clot formation 
were measured on a TEG® 5000 Hemostasis Analyzer 
System (Hemonetics®, USA) as per standard hospital 
protocols.
Standardization of setting
General anesthesia was managed by a group of cardiac 
anesthesiologists using a standardised care protocol. 
The study was conducted in a dedicated cardiac thea-
tre with standardization of ambient air temperature set 
to 21  °C (69.8 F). All patients were fasted 6-h for solids 
and 2-h for clear fluids. Prior to induction of anesthesia 
there was no additional intravenous fluid administered. 
Induction of anesthesia consisted of a standard technique 
using propofol (0.5–1  mg/kg), fentanyl (5–10  μg/kg) 
and a non-depolarizing neuromuscular blocker. Main-
tenance of anesthesia was achieved using sevoflurane 
or isoflurane in 50 % oxygen: 50 % air ratio titrated to a 
bispectral index (BIS) of 40–60. No patient received any 
antifibrinolytic therapy (e.g. tranexamic acid). Intra-oper-
ative autologous hemodilution was not utilised as part of 
the anesthesia technique for any patient. Prior to initia-
tion of CPB fluid intervention was restricted but if clini-
cally indicated, a balanced crystalloid solution was used. 
No colloid solutions were used in the pre CPB period. 
Prior to commencement of CPB heparin (300 U/kg) was 
administered to achieve a therapeutic activated clot-
ting time (ACT) of greater than 480 s. If ACT was sub-
therapeutic repeated boluses of heparin (5000  U) were 
administered. The CPB circuit was primed with 10,000 U 
heparin. For the pump prime crystalloid solution, all 
patients received 2000  ml of Plasma-Lyte 148® (Baxter, 
Sydney, NSW). Cardiopulmonary bypass was performed 
using a membrane oxygenator (Quadrox-i, Maquet Car-
diopulmonary, Hirrlingen, Germany). The pump rate was 
set at 2.4  l  m−2  min and body temperature was main-
tained between 32 and 34  °C (89.6–93.2  F). A standard 
induction cardioplegia solution (Baxter Viaflex®, AHK 
5560, Toongabie, NSW) followed by a maintenance car-
dioplegia solution (Baxter Viaflex® AHK6029, Toongabie, 
NSW) was administered to all patients.
During CPB the ACT was maintained above 480  s 
with additional boluses of heparin if required. If volume 
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supplementation was required during CPB, fluid boluses 
of Plasma-Lyte 148 were used. The use of additional 
blood products was at the discretion of the attending 
clinical perfusionist and anesthesiologist. Normothermia 
was maintained in all patients after separation from CPB 
by using forced air warming devices and a fluid warmer 
ensuring delivery of fluid at 42  °C (107.6  F). At the ter-
mination of CPB, 750 ml of unprocessed residual blood 
remaining within the reservoir and tubing of the CPB cir-
cuit was collected and transferred to a standardised non-
citrated, 1000  ml sterile clear bag (Baxter Healthcare, 
Toongabbie, NSW) over a 5-min period. Systemic hepa-
rin was reversed with a standardised dose of protamine 
(1.5 mg/kg for very 100 U of heparin) to achieve an ACT 
of less than 150 s. If ACT was above 150 s, additional pro-
tamine (50 mg) was titrated in small aliquots. When the 
ACT was less than 150 s, the unprocessed residual blood 
was then reinfused into the patient over a 15-min period.
Blood was sampled from the patient at two key time 
points to evaluate changes in coagulation before and after 
the re-infusion of the unprocessed residual blood.
1. 5  min prior to the reinfusion of the unprocessed 
residual blood.
2. 15 min after the reinfusion of the unprocessed resid-
ual blood.
Sampling was performed by aspirating blood from 
the indwelling arterial catheter using a standard 10  ml 
syringe (Terumo® Corporation, Tokyo, Japan) syringe 
over a 10 s period. In order to assess for contact activa-
tion of the autologous blood from the plastic re-infu-
sion bag, additional blood was sampled from the 750 ml 
unprocessed residual blood in the collection bag, and 
from the CPB circuit itself. All samples underwent stand-
ardised laboratory and TEG coagulation studies, which 
included plasma based laboratory assays of coagulation 
i.e. aPTT, PT, thrombin time (TT), D-dimer, and fibrin-
ogen and platelet count, and measurements of the vis-
coelastic properties of whole blood clot formation using 
TEG. This included measurement of R-time, K-time, 
alpha angle, and maximum amplitude.
Statistical analysis
The study was powered to determine whether the re-
administration of unprocessed residual blood from 
the CPB circuit would have a residual heparin effect on 
the patient. An increase in aPTT by 15  % from base-
line was considered clinically significant. In the context 
of cardiac surgery, pilot data from 63 patients undergo-
ing cardiac surgery at our institution showed that after 
separation from CPB and reversal of systemic heparin 
with protamine (1.5 mg/kg for very 100 U of heparin) the 
mean aPTT was 41  s (SD: 5.0  s). We hypothesized that 
the administration of unprocessed residual heparinised 
blood would increase the aPTT by 15 % (i.e. an increase 
in the aPPT from 41 to 47 s). With an alpha value of 0.05 
and a desired power of 0.90, 8 participants were required. 
In order to observe important changes in other standard 
plasma based laboratory assays and TEG variables, we 
received ethics approval to recruit 40 participants.
Statistical analysis was performed using PRISM 6 
(GraphPad Software Inc., USA). All values analyzed are 
expressed as mean with standard deviation (ST) and 
median with interquartile range (IQR) depending on 
whether the data was normally distributed. Normality 
was tested using the D’Agostino & Pearson omnibus nor-
mality test and the Shapiro–Wilk normality test. Statis-
tical comparisons between data points were done by the 
parametric two tailed paired t tests and non-parametric 
Wilcoxon Signed Rank test. All p values less than 0.05 
were considered statistically significant.
Results
Forty participants consented for the study and received 
the intervention i.e. reinfusion of 750 ml of unprocessed 
residual heparinised blood from the CPB circuit. There 
were no breaches in study protocol. The participant 
demographic data is summarized in Table 1.
Coagulation results
Results of preoperative blood samples are shown in 
Table 2. Results of blood samples from both the 750 ml 
bag unprocessed residual blood and from the CPB circuit 
showed a prolonged aPTT and TT in keeping with a full 
systemic effect of heparin on the intrinsic coagulation 
pathway. As heparin also affects the common coagula-
tion pathway, the INR and PT also were also prolonged 
(Table  3). The key primary outcome measures are sum-
marized in Table 4, which shows the standard laboratory 
coagulation, fibrinolytic and TEG variables. Post reinfu-
sion of the unprocessed residual heparinised blood, the 
mean aPTT decreased from 42 to 35  s (effect size 6  s; 
SD: 6.05; p < 0.0001). Similarly, there were improvements 
of the following coagulation parameters: (1) the mean 
thrombin time decreased from 25  s to 21  s (effect size 
4.08 s; SD: 9.7; p = 0.01), (2) mean fibrinogen increased 
from 1.9 to 2.0 g/l (effect size 0.1 g/l, SD: 0.2; p = 0.05). 
Post re-infusion there were no significant changes in PT 
or INR compared to pre reinfusion values (p = 0.15 and 
p =  0.24 respectively). There was no significant change 
in D-dimer post reinfusion compared to pre reinfusion 
within patients (p  =  0.52). There was no correlation 
between pre-infusion R times and dose of protamine 
administered (Spearman correlation r = −0.09, 95 % CI 
−0.41 to 0.23, p = 0.55).
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Hematological parameters
Post reinfusion of the unprocessed residual hep-
arinised blood there were increases in mean hemo-
globin from 89 to 93  g/l (effect size 4.85  g/l; SD: 
0.69; p  =  0.003) and platelet count increased from 
96 ×  109/l to 118 ×  109/l (effect size 18 ×  109/l; SD: 
31.2; p = 0.0007).
Thromboelastography parameters
Native and heparinase TEG parameters are summarized 
in Table 4. For the heparinase samples, after the reinfu-
sion of the ununprocessed residual blood, the R-time 
(time taken for initial fibrin formation) decreased from 
21 to 12 min (effect size 9.1 min; SD: 16.9; p = 0.0023), 
K-time (speed of clot formation) decreased from 3.9 to 
1.5  min (effect size 1.5  min. SD: 3.6  min; p  =  0.0017), 
alpha angle (rate of clot formation) increased from 59° 
to 65° (effect size: 6.9°; SD: 15.8; p  =  0.012) and MA 
increased from 60  mm to 62  mm (effect size 3.0  mm; 
SD: 5.6, p  =  0.002). There were similar improvements 
in all the native TEG samples, which are summarized in 
Table 4.
Table 1 Patient demographic data
Data is presented as mean (standard deviation)
Demographic variable Value
Age (years) 64 (12)
Gender (males/females) 29/11
Type of surgery (CABG/valvular) 32/8
Euroscore II 7 (3)
Height (cm) 166 (15)
Weight (kg) 81 (24)
BMI (kg/m2) 28 (6)
Dose of heparin (units) 25,000 (7000)
Dose of protamine (mg) 360 (110)
Total time on CPB circuit (mins) 104 (37)
Aortic clamp time (mins) 83 (32)
Table 2 Preoperative hematological, coagulation 
and thromboelastography parameters






















































Tables  3 Hematological, coagulation and  thromboelas-
tography parameters for  the cardiopulmonary bypass 
pump residual blood and transfusion bag blood
Values are mean with standard deviation unless otherwise stated
NR normal range




85 (17) 80 (14)
Platelets (×109/L)
(NR: 150–400)
126 (45) 126 (43)
Prothrombin time (s)
(NR: 11–15)
91 (44) 85 (46)
INR
(NR: <1.4)
7.9 (3.40) 7.2 (3.80)
aPTT (s)
(NR: 22–38)
All values >200 All values >200
Thrombin time (s)
(NR: 13–21)
All values >60 All values >60
Fibrinogen (g/L)
(NR: 2–4)
1.1 (0.27) 1.2 (0.29)
D‑Dimer (mg/L)
(NR: <0.23)




7.1 (2.40) 6.8 (4.60)
K‑time (mins)
(NR: 0–4)
2.4 (3) 0.75 (1.90)
Alpha angle (degrees)
(NR: 47–74)
70 (7.7) 70 (6.90)
Maximum amplitude (mm)
(NR: 54–72)
60 (9.10) 59 (7)
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Outcomes
The mean blood loss from the mediastinal chest drains 
at 24 h post-operatively was 1024 ml (SD 918). Fourteen 
patients (35 %) received a packed red blood cell transfu-
sion. The median number of units transfused was 2 (IQR 
1:1.25). The mean volume of blood transfused was 585 ml 
(SD 447 ml). Five participants (13 %) received post-oper-
ative platelet transfusions. The median number of pooled 
platelets transfused was 1 unit (IQR 1:3) Six patients 
(15  %) received post-operative Fresh Frozen Plasma 
transfusions. The median number of bags of Fresh Frozen 
Plasma transfused was 2 (IQR 1.75:5.75). Four patients 
(10  %) received post-operative cryoprecipitate transfu-
sions. The median number of units of cryoprecipitate 
transfused was 10 (IQR 7:10). There was no correlation 
between postoperative 24-h mediastinal drainage and 
post-infusion R times (Spearman correlation r = −0.004, 
95 % CI −0.33 to 0.32, p = 0.98). The median duration of 
ICU stay was 22  h (IQR 20:42.5). The median length of 
hospital stay was 8.6 days (IQR 8:10).
Discussion
Key study findings
We performed a prospective observational study on 
forty patients undergoing cardiac surgery requiring CPB, 
evaluating the effect of reinfusion of 750  ml of residual 
unprocessed heparinised blood from the CPB circuit 
on coagulation. The reinfusion of unprocessed blood 
increased hemoglobin concentration and platelet count, 
but contrary to the hypothesis resulted in improvements 
of the prolonged common laboratory plasma based 
measurements of coagulation (aPTT, Thrombin Time, 
fibrinogen concentration). Furthermore, post reinfu-
sion there were improvements in the viscoelastic clotting 
properties of blood measured by TEG (R-time, K-time, 
alpha angle, MA).
After the administration of protamine and before the 
reinfusion of the unprocessed residual heparinised blood, 
a post CPB coagulopathy was present as evident by pro-
longation of common laboratory based measures of coag-
ulation and prolonged derangements of both the native 
and heparinase TEG values. Post CPB coagulopathy can 
be caused by a combination of haemodilution, coagula-
tion factor depletion and platelet dysfunction, fibrinolysis 
and residual heparin [4]. We consider a residual hepa-
rin effect to be very unlikely as the TEG R-time did not 
correct with heparinase. Furthermore, there was also no 
TEG evidence of fibrinolysis or platelet dysfunction. As 
the unprocessed residual blood from the CPB circuit is 
heparinized, we expected the coagulation parameters to 
worsen. Contrary to our hypothesis, this effect was not 
observed. Rather, after administration of the residual 
blood there were improvements in the patient’s labora-
tory and TEG parameters of coagulation. The hypothesis 
of excess protamine effect post CPB is also supported by 
the observation that the mean R time (heparinase) in the 
pre infusion sample was greater than the R time in the 
CPB circuit blood. This is unlikely to be due to haemodi-
lution, as there was not a substantial amount of fluid 
given in the immediate post CPB period. Likely, the only 
significant difference between the two time points was 
the administration of protamine. Further evidence to 
support a protamine effect could have been obtained by 
Table 4 Hematological, coagulation and  thromboelas-
tography parameters pre and post infusion of autologous 
residual blood
Values are mean and standard deviation
NR normal range
*p < 0.05 are statistically significant




89 (14) 93 (11) 0.003*
Platelets (×109/l)
(NR: 150–400)




18 17 (3.30) 0.15
INR
(NR: <1.4)
1.6 1.5 (0.29) 0.24
aPTT (s)
(NR: 22–38)
42 (20) 35 (6.4) <0.0001*
Thrombin time (s)
(NR: 13–21)
25 (10) 21 (5.5) 0.01*
Fibrinogen (g/l)
(NR: 2–4)
1.9 (0.51) 2 (0.56) 0.05*
D‑Dimer (mg/l)
(NR: <0.23)




21 (6) 12 (9) 0.0023*
K‑time (min)
(NR: 0–4)
3.9 (3.30) 1.5 (2.50) 0.0017*
Alpha angle (degrees)
(NR: 47–74)
59 (14) 65 (10) 0.012*
Maximum amplitude (mm)
(NR: 54–72)




26 (24) 13 (10) 0.0041*
K‑time (mins)
(NR: 0–4)
5 (5.50) 2.5 (2) 0.012*
Alpha Angle (degrees)
(NR: 47–74)
58 (15) 67 (9.40) 0.0051*
Maximum amplitude (mm)
(NR: 54–72)
61 (11) 65 (7) 0.0078*
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performing anti-Xa assays. Unfortunately, frozen plasma 
samples were not retained to carry out further testing.
We attribute the post CPB coagulopathy observed in our 
study to be a protamine effect. Adverse affects of clot ini-
tiation time, kinetics and platelet function from protamine 
have been previously described [5]. Generally it is assumed 
that 1  mg of protamine neutralizes 100  U of heparin. In 
our study, a higher dose of protamine was administered 
(1.5 mg/kg for very 100 U of heparin). Therefore, the cause 
of the post bypass coagulopathy may be readily attributed 
to an excess protamine effect. Interestingly, the improve-
ments in the aPTT observed after the administration of 
the unprocessed residual heparinised CPB blood may be 
explained by the heparin from the unprocessed residual 
blood neutralizing or “mopping up” excess or residual 
protamine, hence negating the adverse effects of prota-
mine of the coagulation system. Protamine administration 
in excess of heparin has also been shown to have adverse 
effects on collagen-induced platelet thrombus formation 
in addition to impairing the platelet GPIb-vWF interac-
tion necessary for normal hemostasis [6]. Platelet adhe-
sion to the injured vessel wall is essential in hemostasis 
and thrombosis, a process that involves the interaction of 
the platelet glycoprotein Ib with surface bound von Wille-
brand factor (vWF). Since synthetic polycationic peptides 
of the general formula (Arg)n, (Lys)n or (Arg-Lys)n inhibit 
GPIb-vWF interaction, they have been suggested as poten-
tial antithrombotics. Protamine is a highly cationic poly-
peptide, with arginine accounting for approximately 60 % 
of the primary sequence, utilised to neutralise the antico-
agulant effect of heparin after cardiac surgery [7].
The improvement in hemoglobin found post interven-
tion was expected as the pump blood contains a large 
volume of red blood cells. The improvement in platelet 
count was however unexpected and whilst statistically 
significant, is considered of little clinical significance as 
the mean difference between pre and post intervention 
platelet count was only 18 × 109/l. Since the CPB residual 
blood contains a small number of platelets, the overall 
addition of the residual blood to the patients total blood 
volume should lead to a mild decrease in platelet count 
due to a haemodilution effect.
Relationship to previous studies
Only a limited number of studies have compared the 
effect of reinfusion of the unprocessed residual pump 
blood on coagulation and none have used both plasma 
based coagulation and fibrinolysis assays and thromboe-
lastography whole blood analysis. Daane et  al. [8] found 
impaired hemostasis and hyperfibrinolysis after the trans-
fusion of both unprocessed and processed CPB residual, 
compared to preoperative levels. The impaired coagula-
tion and hyperfibrinolysis found post CPB compared to 
pre CPB baseline correlated with our study. Daane et al. 
also found an improvement in the coagulation values as 
time progressed following CPB. However, limitations of 
their study were that the volume of residual blood trans-
fused, and the period over which it was reinfused, was not 
standardized. Therefore it would be difficult to distinguish 
between the effects of time alone and those due to reinfu-
sion of the residual blood from the CPB circuit. In con-
trast, in our study, both the volume of the residual blood 
transfused and the transfusion times were standardized in 
all patients, increasing the validity our findings.
The effects of CPB residual blood content was further 
studied by Flom-Halvorsen et  al. [9] who evaluated the 
hemostatic and inflammatory markers in 40 patients 
undergoing CPB. The hemostatic and immunologic 
systems were moderately activated in the autologous 
blood remaining in the extracorporeal circuit, whereas 
the mediastinal shed blood was highly activated in all 
aspects. Autotransfusion had no correlating clinical 
side-effects and the subsequent exposure to allogeneic 
blood products was minimal. Similar to the findings of 
our study, Flom-Halvorsen et  al. observed that blood 
from both the unprocessed residual pump blood bag and 
bypass circuit were analyzed and found to have globally 
impaired coagulation. As the unprocessed residual CPB 
blood is heparinized, it may have adverse effects on the 
intrinsic and common coagulation pathways. Thrombin 
time is also sensitive to heparin and was also prolonged 
in our study, again suggestive of a heparin effect. Finally, 
Campbell et al. [10] evaluated the impact of cell salvage 
during cardiac surgery on the thromboelastomeric coag-
ulation profiles. Residual CPB volume was processed and 
transfused after surgery in the cell salvage group and the 
residual volume was transfused unprocessed in the con-
trol group. Similar to our findings, there was an increase 
in the clotting time (K-time) and clot formation time 
(R-time) in patients post separation from bypass com-
pared to baseline values. Cell salvage of the residual CPB 
volume reduced platelet numbers and prolonged clot 
formation time and maximum clot firmness. However, 
unlike our study comparisons were made with pre surgi-
cal values and not immediate pre transfusion values.
Strengths and limitations
Our study also has several methodological strengths. 
Information on detailed changes in both the standard 
plasma based assays for coagulation and TEG were per-
formed supporting the validity of our findings. Analy-
sis of the blood from the CPB circuit in addition to the 
unprocessed heparinised blood from the transfusion 
bag has further strengthened the internal validity of the 
study. This ensured there were no additional study con-
founders and all patients were infused with unprocessed 
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heparinised residual blood with similar laboratory coagu-
lation parameters. Standardization of the doses of hepa-
rin and protamine ensured consistency between patients, 
and a more accurate interpretation of our findings. 
Although our institution is a major tertiary teaching hos-
pital with a high caseload of complex cardiac procedures, 
it is not possible to generalize the results of this study to 
other centers, different types of cardiac surgery, or cen-
tres that use different heparin and protamine protocols. 
This is a single centre study, which may limit the external 
validity of our findings. However our hospital has all the 
typical characteristics of a tertiary institution in a devel-
oped country and a recent comparative study confirmed 
that its patients and their outcomes were equivalent to 
those of other tertiary hospitals in Australia [11].
There are also several limitations to our study. First, 
the trial was small and only powered to show changes in 
the aPTT. However changes in the other secondary out-
comes, particularly the TEG variables are important and 
allow a greater understanding of the changes observed. 
There is potential for other confounders to have influ-
enced the outcomes measured. In particular, cardiac sur-
gery involves several heterogeneous surgical techniques, 
pathologies and patients, which may not have been 
exactly similar in our small sample size. Participants were 
used as their own controls, and the study design could 
have been strengthened by randomizing patients to com-
pare those that received unprocessed residual CPB blood 
and those that did not. Finally, further tests for special 
markers of coagulation activation (e.g. prothrombin frag-
ments, plasmin-anti-plasmin, plasminogen activator 
inhibitor-1, and interleukin-6) were not be carried out, 
which may have provided further information about the 
effects of pump blood on coagulation activation.
Conclusion
This study demonstrates that after separation from CPB 
and systemic heparin reversal with protamine, the rein-
fusion of 750 ml of unprocessed heparinised blood from 
the CPB circuit improved hemoglobin concentration and 
platelet counts. Contrary to the findings of other studies 
[8–10], reinfusion of the unprocessed heparinised blood 
resulted in no adverse effects on the coagulation system 
measured by both the common laboratory plasma based 
measurements of coagulation and thromboelastrography.
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